

## ASX Media Release Biological Testing Sr-HT-Gahnite Further Safety Evidence

SYDNEY 5<sup>th</sup> August 2022– Allegra Orthopaedics Limited (Allegra) (ASX: AMT) is pleased to announce further evidence demonstrating the safety of the material, Sr-HT-Gahnite, under good laboratory practice (GLP) conditions.

The in-life phase of the large animal study performed at SAHMRI-PIRL (South Australian Health and Medical Research Institute – Preclinical, Imaging and Research Laboratories) is complete, with full fusion and histological analysis underway.

In addition, small animal testing was also conducted at NAMSA USA. When subjected to biological testing, the Sr-HT-Gahnite Cervical Spinal Fusion Cage proved to be non-cytotoxic, non-sensitising, non-irritating, and non-pyrogenic. When implanted in rabbits for up to 13 weeks, the material elicited no reaction from the local tissue, further reinforcing the biological safety of the device.

We continue to receive positive testing results instilling further confidence that Allegra is on track to obtain a 90 day FDA 510(k) clearance for the United States in early 2023

This announcement has been authorised for release by Jenny Swain CEO

Contact details:

**Robyn Slaughter** Company Secretary D: +61 2 8072 1435

## ABOUT ALLEGRA ORTHOPAEDICS:

We aim to help bring the freedom and happiness of pain-free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world-wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributors of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventor